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Abstract
The classification, pathobiology and clinical management of chronic myelomonocytic
leukaemia (CMML) are reviewed. Three important issues are identified: (1) CMML should
be recognised as a unique clinical entity and as distinct from myelodysplastic syn‐
dromes (MDSs). Somatic mutations of a restricted set of genes are frequent in CMML. (2)
Risk stratification for CMML patients should utilise new CMML‐specific prognostic
scoring systems. (3) Until randomised clinical trials have defined the role of new drugs
(especially of the hypomethylating agents), treatment must focus on the main symp‐
toms and aim at quality‐of‐life improvement.
Keywords: chronic myelomonocytic leukaemia, myelodysplastic/myeloproliferative
syndrome, somatic mutations, prognosis, therapy
1. Introduction
Chronic myelomonocytic leukaemia (CMML) is a rare haematological neoplasm character‐
ised by a persistent peripheral blood monocytosis and both myelodysplastic and myeloproli‐
ferative features. Our understanding of this disease has undergone profound changes in recent
years. Initially it was classified as a subtype of myelodysplastic syndromes (MDSs), and it is
now recognised as a unique disease. This reclassification has been substantiated by recent
advances in the genetic and molecular pathogenesis of CMML, which have confirmed that
CMML is biologically distinct from MDS with a different pattern of somatic mutations and a
different molecular ontogeny [1].  In addition, CMML‐specific prognostic scoring systems
(CPSSs) have been established by various groups. These differ from those commonly used in
MDS and, for the first time, also include molecular markers. Hopefully, these efforts will
culminate in CMML‐specific treatments in the near future. The following chapter will summa‐
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rise these developments starting with a discussion of CMML classification and ending with an
outlook on new treatment approaches.
2. Diagnosis and classification
The first reports comprising significant numbers of patients with CMML were published
around 40 years ago [2, 3]. These early series already noted a considerable clinical diversity,
describing myelodysplasia and cytopenia accompanied by leukocytosis and other myelopro‐
liferative symptoms such as splenomegaly. Nevertheless, the first French–American–British
(FAB) Cooperative Group classification of MDS in 1982 included CMML as a MDS subtype,
emphasising its dysplastic features but not its diversity [4]. The diagnostic criteria proposed
included more than 1 × 109/L blood monocytes, bone marrow blasts of 20% or less, peripheral
blasts <5%, and bone marrow dysplastic features in at least one haematopoietic lineage
(Table 1). To account for the clinical diversity mentioned earlier, the FAB group later intro‐
duced a subclassification by dividing patients into two groups based on the leukocyte count
at diagnosis [5]. Patients with a leukocyte count above 13 × 109/L were considered to have a
myeloproliferative form (MPD‐CMML), those with a leukocyte count below 13 × 109/L a
myelodysplastic form (MDS‐CMML). This arbitrary threshold has been controversial, and its
clinical relevance was tested in several cohorts of patients with CMML. In a retrospective
analysis of 158 patients (81 patients with MDS‐CMML and 77 patients with MPD‐CMML),
Germing et al. found no significant difference in 2‐year overall survival (OS) between these
subgroups. The likelihood of transformation to AML was higher in the MDS‐CMML group,
but this difference was not statistically significant [6]. Voglova et al. [7] described the frequent
transition of MDS‐CMML to MPD‐CMML, suggesting that the two subgroups might represent
different stages of the same disease rather than two different entities. Onida et al. analysed a
cohort of 213 patients with CMML (35% with MDS‐CMML and 65% with MPD‐CMML) and
could also not find a statistically significant difference in survival after 12 months. There was,
however, a trend for a better survival of patients with MPD‐CMML after 16 months [8]. To
resolve these diagnostic inconsistencies, the WHO (2001) classification of myeloid neoplasms
defined a new group of overlap syndromes called myelodysplastic/myeloproliferative
diseases (MDS/MPS). Besides CMML, atypical (bcr‐abl negative) CML (aCML), juvenile
myelomonocytic leukaemia (JMML) and myelodysplastic/myeloproliferative disease, unclas‐
sifiable (MDS/MPS‐U) were placed in this group [9]. The details of the diagnostic criteria for
CMML are listed in Table 1. Further, two CMML subtypes were recognised: CMML‐1 with
PB blast <5% and <10% BM blasts and CMML‐2 with 5–19% PB blasts and 10–19% BM blasts.
The prognostic significance of these subgroups was confirmed in a reanalysis of the Düsseldorf
registry of 300 CMML patients. The 5‐year risk of transformation to AML was 63% for patients
with CMML‐2 compared to only 18% for patients with CMML‐1 [10]. More recently, the same
group found that further subclassification of CMML based on medullary blast count could
provide additional prognostic information [11]. Patients with the new subtype of CMML‐0
(defined as <5% medullary blasts) had a better prognosis than those with CMML‐1 (OS 31 vs.
19 months). These results have not yet been reproduced in an independent cohort.
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The 2008 revision of the WHO classification has maintained the main diagnostic criteria for
CMML, with one additional feature [12]. In particular, the recognition of an associated
eosinophilia is an important clue to an underlying rearrangement of the platelet‐derived
growth factor receptor, alpha or beta polypeptide (PDGFRA/B) gene. If this molecular lesion
is found, the case should be classified as a myeloid neoplasm with eosinophilia associated with
PDGFRA/B rearrangement. These patients often respond exquisitely to imatinib [13].
Diagnostic difficulties most commonly arise in the distinction between CMML and aCML,
because a monocytosis can be present in the latter. In difficult cases, the pattern of somatic
mutations might be exploited in the future [14, 15]. For example, the co‐existence of a serine/
arginine‐rich splicing factor 2 (SRSF2) and a ten–eleven translocation‐2 (TET2) mutation
suggests CMML, a SET nuclear proto‐oncogene binding protein1 (SETBP1) mutation points
towards aCML.
The presence of a peripheral blood monocytosis is a diagnostic prerequisite for the diagnosis
of CMML but can also be caused by a number of reactive conditions. In patients with clinical
or laboratory signs of inflammation, such as fever, arthritis, increased C‐reactive protein or
elevated erythrocyte sedimentation rate, the diagnosis of CMML should be made with caution.
Often, re‐evaluation is necessary once the signs of inflammation have subsided. A recent study
suggests that the distinction between reactive monocytosis and CMML might be possible by
immunophenotyping, but this finding needs further confirmation in independent studies [16].
FAB classification WHO classification
Myelodysplastic syndrome MDS/MPD overlap syndrome
PB Monocytosis >1 × 109/L
Myeloblasts <5% in PB, <20% in BM
Dysplasia in one or more haematopoietic lineage
PB Monocytosis >1 × 109/L
Myeloblasts <20% in BM
No BCR‐ABL1 fusion gene
No PDGFRA/PDGFRB rearrangement
Dysplasia in one or more myeloid lineage
 If lacking: acquired clonal cytogenetic abnormality
Subclassification
MDS‐CMML: WBC < 13 × 109/L
MPD‐CMML: WBC > 13 × 109/L
Subclassification
CMML‐1: Blasts PB < 5%, BM < 10%
CMML‐2: Blasts PB 5–19%, BM 10–19%
FAB, French‐American‐British; PB, peripheral blood; BM, bone marrow.
Table 1. Comparison of the FAB and WHO classifications of CMML.
3. Epidemiology and clinical features
CMML is a rare disease of the elderly. Two recent population‐based studies found a similar
age standardised annual incidence rate of approximately 0.3–0.4/100,000/year [17, 18]. Median
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age was 70–75 years, and there was a slight male predominance. The study from the Nether‐
lands found that the diagnosis was made in a non‐university setting in 78%, indicating that
many patients are managed by practising haematologists. This observation emphasises the
need to perform clinical studies also in a community‐based setting to include as many patients
as possible. The 5‐year relative survival was poor (16–20%) in this study and did not improve
over time. Therapy‐related CMML (t‐CMML), defined as occurring after chemotherapy,
radiotherapy or both, is considered rare but was found in 10% in a recent MD Anderson Cancer
Centre (MDACC) series. Patients with t‐CMML had a significantly worse median OS com‐
pared to patients with de novo disease (13 vs. 20 months), most likely due to a higher rate of
intermediate‐ or high‐risk cytogenetic abnormalities [19]. Similar results were reported in a
series from the Mayo Clinic (median OS 11 vs. 20 months) [20].
3.1. Clinical features
Monocytosis can be an incidental finding in an otherwise asymptomatic patient. In other cases,
it is accompanied by anaemia (in about 50% of patients at diagnosis) and/or thrombocytopenia.
Frequently, a haematological prodrome, for example an unclear thrombocytopenia, can be
observed. In about 30–60% of patients, leukocyte counts >13 × 109/L are found, often with
clinical signs of myeloproliferation such as splenomegaly in around 30% [8]. Hepatospleno‐
megaly is more frequent (25–50% of patients) in the myeloproliferative variant [21]. Many
patients experience constitutional symptoms, fatigue, night sweats and occasionally bone pain.
In contrast to MDS, involvement of various organ systems has been described in CMML
patients. Skin lesions can be an indicator of leukemic transformation [22]. Serosal infiltration
causing pleural or pericardial effusion is quite frequent and can be difficult to treat [23]. Local
instillation of mitoxantrone, in combination with systemic chemotherapy, has been used with
some success in such cases. A case of widespread gastric involvement mimicking metastatic
gastric carcinoma was recently seen in our practice (own unpublished observation). Cases of
uncontrollable haematuria caused by CMML involvement of the urogenital tract have also
been described [24, 25].
An association with autoimmune‐mediated disorders is frequently seen in CMML. For
example, in a study of 123 CMML patients, 20% had at least one associated disorder, most
commonly immune thrombocytopenia (ITP), gout or psoriasis [26]. Importantly, ITP seems to
respond well to standard treatment used in primary ITP, such as steroids and splenectomy [27].
Over time transformation into acute myeloid leukaemia occurs in approximately 30% of
patients. The rate of transformation varies according to the risk profile at diagnosis. A sudden
rise in the leukocyte count does not necessarily indicate leukemic transformation but can be
an expression of increased myeloproliferation. A careful evaluation of the blast count is
important in this situation.
3.2. Laboratory and pathologic findings
In the peripheral blood, monocytes can be normal or display atypical features such as fine
nuclear chromatin or abnormal nuclear lobulations. In the myeloproliferative variant, median
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absolute monocyte counts ranging from 4.2 × 109 to 7.7 × 109/L have been reported [21]; in
general, the median monocyte count is around 2 × 109–3 × 109/L. Morphologic evidence of
dysgranulopoesis is often seen in CMML, while dysmegakaryopoiesis and dyserythropoiesis
are less frequent. The bone marrow is usually hypercellular with an elevated myelopoiesis‐to‐
erythropoiesis ratio. By definition, the blast count is <20%. When enumerating blasts, mono‐
blasts and promonocytes should be included. A helpful morphological classification of
monocytic precursors, particularly defining promonocytes in CMML, is available [28].
Monocytic precursors including monoblasts are frequently CD34 negative. Therefore, there is
a risk of underestimating the blast number by relying only on CD34 staining in bone marrow
biopsies or flow cytometry. The medullary blast count should be determined in good quality
bone marrow aspirates that have also been stained for esterase.
4. Cytogenetics
Clonal chromosomal abnormalities occur in approximately 30% of patients with CMML [29,
30]. The most frequent abnormalities are +8 (20–25%), -Y (20%), monosomy 7 and deletion 7q
(14%), deletion 20q (8%). A complex karyotype was found in 11%. In contrast to MDS, del5q
is very rare. Patients with an abnormal karyotype tended to be older, more anaemic and had
a higher peripheral blood and bone marrow blast count [30]. Additional sex combs like 1
(ASXL1) mutations were associated with an abnormal karyotype, SRSF2 mutations with a
normal karyotype [31]. Cytogenetic abnormalities were also found to be of prognostic
relevance (see Section 6).
5. Molecular findings
Large‐scale sequencing studies in myeloid malignancies have lead to important insights into
disease biology. These studies have shown one of the highest rates of acquired somatic
mutations in CMML patients. For example, in a study by Meggendorfer et al. [31], at least one
mutation in 9 recurrently mutated genes was found in 93% of 275 CMML patients. This study
and several others also identified clear differences in frequency of mutations in key cellular
pathways between CMML and MDS. In addition, the genomic landscape in CMML demon‐
strates a much smaller molecular heterogeneity compared to a more diffuse mutation profile
in MDS [32].
Table 2 summarises the frequency of mutations sorted by the cellular pathway affected [33].
In contrast to MDS, genes serving in different signalling pathways are frequently mutated in
CMML. As a biological correlate, an increased sensitivity to GM‐CSF has been found in vitro.
It appears to be mediated by the STAT pathway, since inhibition of proliferation was observed
by the JAK2 inhibitor ruxolitinib [34], indicating the therapeutic potential of these agents or
anti GM‐CSF monoclonal antibodies.
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Cellular pathway Gene Frequency (%)
Signalling KRAS 8%
NRAS 11%
CBL 10%
JAK2 10%
SETBP1 10%
RNA splicing SRSF2 46%
ZRR2 10%
U2AF35 10%
Epigenetic regulation TET2 58%
ASXL1 50%
EZH2 8%
Transcription RUNX1 15%
Numbers based on Refs. [1, 33].
Table 2. Frequency of somatic mutations in CMML.
Significant differences were also found in the frequency of mutations affecting RNA splicing.
While mutations in SRSF2 are very common in CMML (40–45%), they are found in <10% of
MDS patients, with an enrichment in subtypes with blast excess [31, 32]. Similarly, mutations
in epigenetic regulators, among them TET2 and ASXL1, occur much more frequently in CMML
than in MDS. For example, using next generation sequencing, TET2 mutations were found in
only 39 of 320 patients with MDS (12%) but in 16 of 35 patients with CMML (46%) [35].
TET2 belongs to the ten–eleven translocations family of proteins and participates in the
conversion of 5‐methylcytosine to 5‐hydroxymethylcytosine. TET2 function depends on the
presence of alpha‐ketoglutarate, which is produced by isocitrate dehydrogenase 1 and 2
(IDH1/2). TET2 and IDH1/2 mutations are mutually exclusive and lead to promoter
hypermethylation [36], providing a potential explanation for the mode of action of the hypo‐
methylating agents (HMAs). TET2 mutations appear to be particularly important for CMML
pathophysiology and development of its characteristic phenotype. In a series of elegant
experiments with samples from CMML patients, Itzykson et al. [37] have shown that early
clonal dominance, particularly in a TET2‐mutated clone, promotes granulomonocytic differ‐
entiation. Knockdown experiments of TET2 in human cord blood CD34+ cells have also found
perturbation of myeloid development with promotion of the granulomonocytic lineage [38].
Furthermore, the early occurrence of TET2 mutations could predetermine the acquisition of
secondary mutations, for example in SRSF2, leading to characteristic mutational combinations.
Besides its role in understanding disease biology and classification, mutational analysis is
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likely to impact on various clinical aspects, for example prognostication (discussed below) and
prediction of treatment response.
6. Prognosis
6.1. Individual parameters
The importance of the medullary blast count as a prognostic variable was discussed before
and forms the basis of the subclassification of CMML into CMML‐1 and CMML‐2. The
prognostic significance of cytogenetic abnormalities was first described by the Spanish MDS
group in a cohort of 414 CMML patients. Three risk cytogenetic categories were identified in
that study: low risk (normal karyotype and loss of chromosome Y as single abnormality),
intermediate (all other single or double abnormalities) and high risk (trisomy 8, abnormalities
of chromosome 7 and complex karyotype). The OS at 5 years for these risk groups was 35, 24
and 4%, respectively [29]. In a recent large collaborative analysis of 409 patients with CMML,
slightly different cytogenetic risk groups were defined: low risk [normal, sole -Y, sole der(3q)],
intermediate (all karyotypes not belonging to high or low risk group) and high risk (complex
and monosomal karyotype). In contrast to the Spanish study, trisomy 8 was placed in the
intermediate risk group. The median OS was 41, 20 and 3 months, respectively [30]. The
mutational status of several genes has also shown to be of prognostic relevance, although
conflicting results were found in different cohorts. For example, mutations in TET2 were
associated with no effect on outcome in one study [35] and with an adverse outcome in another
study [39]. In a large series of 312 patients tested for a number of genes, only ASXL1 mutations
had a negative prognostic value in multivariate analysis [40]. This finding was confirmed in a
larger cohort of 466 patients (including the 312 patients from the original series) [41]. In another
large study of 275 CMML patients, no effect of SRSF2 mutations on survival was observed [31].
In summary, ASXL1 mutational status has emerged as a robust prognostic variable and has
thus been incorporated into CPSSs, as discussed below.
6.2. Prognostic scoring systems
A number of prognostic scoring systems for CMML patients have been developed in the past,
none of which however was universally used [42]. This is in contrast to MDS where the
International Prognostic Scoring System (IPSS) and its recently revised version (IPSS‐R) form
the basis of treatment decisions in studies as well as in clinical practice. More recently, novel
CMML‐specific scoring systems have been described that incorporate cytogenetic or molecular
information. These scores appear to be more precise and will be discussed further. First, the
CPSS has been developed by the Spanish MDS group in a cohort of 558 patients [43]. It uses
WHO/FAB subtype, a CMML‐specific cytogenetic risk categorisation and transfusion depend‐
ence to divide patients into four risk groups (low, intermediate‐1 or intermediate‐2, and high)
with a median OS of 72, 31, 13 and 5 months, respectively). This model demonstrated for the
first time that cytogenetic abnormalities are of prognostic relevance in CMML. Notably, it
highlights that the significance of individual cytogenetic abnormalities can vary between
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CMML and MDS. For example, trisomy 8 carries an adverse prognosis in CMML but not in
MDS. The CPPS has been externally validated in a cohort of 274 patients. Second, the French
cooperative MDS group (GFM) developed a prognostic model that included the presence of
ASXL1 mutations, age (>65 years being an adverse prognostic factor), and haematological
parameters (WBC > 15 × 109/L, platelet count <100 × 109/L and haemoglobin <11 g/dl being
adverse factors). It stratifies patients into 3 risk categories with a median OS of not reached,
38.5 and 14.4 months, respectively, and has also been externally validated [40]. Lastly, the
group from the Mayo Clinic has improved on their original prognostic model by incorporating
ASXL1 mutational status. This new score has been termed Mayo Molecular Model (MMM)
and was developed in corporation with the GFM [41]. Five risk factors affected median survival
in multivariate analysis: ASXL1 mutation status, absolute monocyte count >10 × 109/L,
haemoglobin levels <10 g/dl, platelet count <100 × 109/L, and circulating immature myeloid
cells. It divides patients into four risk categories with median survival of 97, 59, 37 and 16 
months, respectively. Importantly, this new score can identify low risk patients (by the original
Mayo Clinic score) with a high risk of progression (without or with ASXL1 mutation: median
survival 99 vs. 44 months).
Particularly when considering allogeneic stem cell transplantation, prognostication in younger
CMML patients, defined as younger than 65 years, is crucial. A retrospective analysis of 261
such patients has identified several adverse prognostic factors that differ from those in the
general CMML population. In addition to anaemia and ASXL1 mutations, an increased
circulating blast count, SRSF2 mutations and the cytogenetic risk classification of the Mayo‐
French consortium were independently prognostic. In this study, ASXL1 and SRSF2 mutation
status did not influence response to HMAs or transplantation outcome [44].
In summary, it is evident that CPSSs that include cytogenetic and/or molecular parameters
should be employed in the future.
7. Therapy
7.1. General considerations
Although providing little prognostic information, the concept of a myelodysplastic and a
myeloproliferative variant of CMML is helpful in guiding treatment. In particular, patients
suffering mainly from uncontrolled myeloproliferation may require rapidly acting
cytoreductive treatment. On the other hand, patients with symptoms due to marrow failure
require treatment aiming at restoring adequate peripheral blood counts. No treatment so far
has been shown to prolong survival or to alter the natural history of the disease. However,
randomised studies in CMML patients have not yet been performed, with one exception [45].
Typically, CMML patients (excluding those with MPD‐CMML) were included in MDS trials,
albeit in small numbers precluding a meaningful statistical analysis. For example, in the AZA‐
001 trial that led to the registration of azacitidine in higher risk MDS only 16 of the 358 enrolled
patients had CMML [46].
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For the treatment of lower risk patients with symptomatic anaemia, erythropoiesis‐stimulating
agents (ESA) might be helpful. A 64% erythroid response rate and transfusion independence
in 33% of patients was recently reported in a retrospective analysis of 94 CMML patients. Low/
intermediate‐1 CPSS and low endogenous erythropoietin levels were predictors of response
[47]. ESA's should be used with caution in patients with myeloproliferative CMML because of
the risk of splenic enlargement or rupture.
Younger patients with high‐risk features (for example intermediate‐2 or high risk in the MMM)
should be evaluated for eligibility for allogeneic stem cell transplantation. Whether high‐risk
patients benefit from early treatment with HMAs, as in high‐risk MDS, must be tested in
prospective randomised trials.
7.2. Stem cell transplantation
Allogeneic stem cell transplant (allo‐SCT) still remains the only curative option for patients
with CMML and should be considered in younger patients with high‐risk disease. So far all
reports on allo‐SCT in CMML have been retrospective and many included patients with
CMML as well as MDS. CMML-specific patient series have only been recently reported, with
the EBMT series comprising 513 patients being by far the largest [48]. The median age was
53 years, clearly younger than the median age of CMML patients in general. The non‐relapse
mortality at 1 and 4 years was 31 and 41%, respectively. The incidence of relapse at 4 years was
32%, resulting in an estimated 4‐year relapse free survival of 27% and OS of 33%, respectively.
Of note, no influence of procedure‐related parameters such as stem cell source, type of donor
or T‐cell depletion on outcome was found. Importantly, the only significant parameter
associated with an improved outcome was the presence of a complete remission at the time of
transplantation. A similar trend was also found in a smaller study [49]. Thus, allo‐SCT can
provide long‐term remissions in about 30% of younger patients. The procedure should be
performed after achievement of the best possible remission status, either with combination
chemotherapy or with HMAs. Although the best preparatory regimen is not known, a recent
retrospective study of 83 patients from the MDACC supports the use of HMA before allo‐SCT.
The study found a significantly lower incidence of relapse at 3 years post transplant in patients
treated with HMA, compared to patients treated with other agents (22 vs. 35%, p = 0.03),
resulting in a better 3‐year progression‐free survival [50]. A selection bias might confound
these interesting results, since patients who do not progress while treated with HMA (median
of 6 cycles in the study) are likely to have a less aggressive disease.
7.3. Cytoreductive treatment
In patients with symptoms mainly caused by myeloproliferation, cytoreductive treatment is
indicated. Several studies have demonstrated the effect of the topoisomerase‐I inhibitor
topotecan in patients with CMML. As a single‐agent, complete response rates of up to 28%
have been described [51]. Similarly, clinically meaningful responses, including improvement
of life threatening pericardial and pleural effusions, as well as cytopenias were reported for
the topoisomerase‐II inhibitor etoposide [52]. However, in a randomised study of 105 patients
from 43 European centres, hydroxyurea was found to be superior to etoposide in terms of the
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response rate (60 vs. 36%) and OS (20 vs. 9 months) and has thus remained the treatment of
choice for palliative cytoreduction in CMML patients [45]. The experience with intensive
chemotherapy in CMML has been disappointing [53]. AML‐like induction therapy is only
rarely used, usually as a preparatory regimen before allogeneic stem cell transplantation in
patients with an aggressive disease.
7.4. Hypomethylating agents
The introduction of the HMAs azacitidine and decitabine is likely to transform clinical
management of CMML. A growing number of studies have shown considerable single agent
activity with very low toxicity. In the largest study so far (76 patients from France, Cleveland
Clinic and Lee Moffitt Cancer Center), a response rate of 43%, with 17% complete remissions,
was found [54]. Of note, 46% had a proliferative form of CMML, as defined by a leukocyte
count of >13 × 109/L. In that study, the presence of more than 10% bone marrow blasts and
palpable splenomegaly had a negative impact on survival. A smaller Italian retrospective
study analysed the response in 31 patients with CMML (42% with CMML‐1, 58% with CMML‐
2) who were treated with azacitidine at a dose of 75 or 50 mg/m2 for 7 days. The overall response
rate was 51%, including 45% achieving complete remission [55]. A study from the Austrian
Azacitidine registry reported on the outcome of 48 patients treated with azacitidine at 11
different centres [56]. Mean age was 71 years; 40% had CMML‐1; 60% had CMML‐2; and
splenomegaly was found in 48%. Even in this unselected cohort with several high‐risk features,
there was a surprising response rate of 70%, including 22% complete responses. Matched
paired analysis suggested a better 2‐year‐survival when compared to best supportive care (62
vs. 41%, p = 0.067).
Other studies have examined the activity of the related HMA decitabine in CMML. One of the
first reports was published by the MDACC group on 19 patients with CMML, and a complete
response rate of 58% was found. The dose of decitabine was 100 mg/m2 per course, given in
three different treatment schedules [57]. In a phase 2 trial from the GFM, 39 patients with
advanced CMML were treated with decitabine at a dose of 20 mg/m2 for 5 days. The median
number of treatment cycles was 10 and the overall response rate 38%, OS at 2 years was 48%.
Interestingly, the presence of ASXL1 mutations had no significant impact on response or
survival in that study [58]. A review of CMML patients that were included in several phase 2
and one phase 3 trials of decitabine in MDS was done by Wijermans et al. [59]. Among a total
of 271 patients, 31 CMML patients were identified. The overall response rate was 25% with
14% CR, and 39% had stable disease. The treatment schedule was different than in the GFM
study, and many patients received only a few cycles of therapy (median of four cycles).
Reliable and easily available predictors of response to treatment with HMA have not yet been
identified. Although a correlation of response with TET2 mutational status would seem
plausible, this was not found in two different studies [58, 60]. Likewise, no other somatic
mutation frequent in CMML proved to be predictive of response.
A small retrospective analysis has shown activity of decatibine and azacitidine in reducing
spleen size in CMML patients. Spleen size was measured by physical examination, and
complete or partial spleen response was found in 5 of 11 patients (45%) [61].
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Although these data are promising and have led to the registration of both drugs for the
treatment of CMML, data from phase 3 trials demonstrating a survival benefit are not yet
available. Also, the optimal treatment schedule and treatment duration need to be defined.
The results of an ongoing randomised trial (DACOTA trial) comparing hydroxyurea to
decitabine in patients with advanced proliferative CMML are, therefore, eagerly awaited. This
trial is conducted in three countries (France, Italy and Germany) and will include about 160
patients. The primary endpoint is progression‐free survival.
7.5. Investigational agents
A large number of investigational agents have been tested in CMML, among them tyrosine
kinase inhibitors, farnesyltransferase inhibitors, immunomodulators and most recently JAK2
inhibitors. The experience with many of these approaches is limited to small phase 1 or phase
2 studies that have not been further developed, either because of limited activity or because
of significant toxicity.
Imatinib has shown no effect in CMML patients without a PDGFRB rearrangement. Because
CMML cells often have RAS activating mutations, drugs targeting this pathway have been
tested. In a phase 2 trial, 35 patients with CMML were treated with lonafarnib (200–300 mg
twice daily), one CR and 7 haematological improvements were reported. Major toxicities were
gastrointestinal, fatigue, fever and hypokalemia [62]. Similar results were observed for
tipifanib in a study of 10 CMML patients [63]. In several patients treated with lonafarnib, a
significant increase in the white blood cell count was noted, sometimes accompanied by
oedema and respiratory symptoms. This complication resolved quickly after discontinuation
of lonafarnib and treatment with dexamethasone [64]. Disappointingly, translational studies
have shown no correlation between responses and inhibition of farnesyl transferase.
Interesting results have been found in a study targeting angiogenesis in MDS and CMML
patients with a combination consisting of melphalan (2 mg/day) and lenalidomide (10 mg/
day). Changes in circulating endothelial cells and plasma VEGF levels served as biomarkers
of angiogenesis. The response rate was 33% in CMML patients (3/9), all of which had a
proliferative form of the disease. Interestingly, there was a correlation between response and
angiogenesis inhibition in these patients. Dose reductions were frequently necessary, but many
patients were cytopenic already at baseline [65].
Most recently, a multicentre phase 1 trial (only published in abstract form) tested the JAK2
inhibitor ruxolitinib in 19 CMML patients. All patients had CMML‐1 and those with significant
cytopenias were excluded. No dose limiting toxicity was noted. Although there were few
haematologic responses, a frequent improvement of splenomegaly and B symptoms was
found. A phase 2 trial testing ruxolitinib at a dose of 20 mg BID is planned [66].
8. Summary and outlook
CMML is a rare myeloid neoplasm with an overall poor prognosis. Important progress has
been made in recent years in several aspects. First, the recognition of CMML as a unique disease
Chronic Myelomonocytic Leukaemia
http://dx.doi.org/10.5772/63193
173
entity, separated from the myelodysplastic syndromes, is an important step towards optimis‐
ing clinical management. Second, the introduction of CPSSs will improve patient selection in
clinical trials. Phase 3 clinical trials in CMML patients will soon define the role of HMA in
treatment. The elucidation of the mutational landscape in CMML has not provided disease‐
specific mutations but highly characteristic mutational combinations, particularly of TET2 and
SRSF2. These insights into molecular pathology are very likely to provide the basis for the
development of novel therapeutic agents. Individualised therapies based on the predominant
gene mutations could be envisaged. For example, while patients with TET2 mutations are
treated with HMA, in patients with mutations affecting signalling, specific pathway inhibitors
might be more potent. Clearly, novel strategies and agents are needed for this still difficult to
treat disease.
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